Biodesy will use the funds to develop and commercialise its technology to enable real-time measurement of protein conformational change.
It said that existing technologies are not capable of measuring protein conformational changes with high resolution and in real time.
5AM Ventures managing partner Andrew Schwab said, “Biodesy has the potential to help transform our understanding of how proteins work by delivering the first real-time, high-throughput system for measuring changes in protein structure caused by molecular interactions.
Today AltAssets reported that one of the company’s backers, 5AM Ventures, is looking to pull in $240m of new capital in what it expects will be a swift fundraise.
Copyright © 2013 AltAssets